人参皂苷Rb_1对肝纤维化血清学指标及病理学改变的相关性分析

The Empirical Control Test of Using Panaxsaponin Rg_1 and Rb_1 on Hepatic Fibrosis

目的:观察三七总甙单体成分人参皂苷Rb1对实验性肝纤维化的作用。方法:用50%四氯化碳致大鼠肝纤维化模型,共35天,同时给予三七总皂甙单体成分人参皂苷Rb1治疗,于第5周(实验结束)时检测肝功能、血清Ⅲ型前胶原(pCⅢ)、透明质酸(HA)、层粘连蛋白(LN),同时分离肝组织光镜观察肝组织病理变化。结果:三七总皂甙能改善肝纤维化大鼠的肝功能,降低血清pCⅢ、HA、LN含量;三七总皂甙能明显减轻肝组织胶原的沉积,改善肝纤维化程度;而人参皂苷Rb1不能改善肝纤维化程度;血清pCⅢ、HA与肝纤维化病理分级有相关关系。结论:血清pCⅢ、HA是反应肝纤维化程度的可靠指标;人参皂苷Rb1不具有抗肝纤维化的作用,人参皂苷Rb1不是三七总甙抗肝纤维化有效成分之一。

Objective ： To investigate the effect of Panaxsaponin and Rbl on hepatic fibrosis, which are two of the main ingredients of Panax Notoginsenosides. Methods ： Make the rats models of hepatic fibrosis by using 50% CCl4, at the same time, give the Panaxsaponin Rbl on different doses and Panax Notoginsenosides by hypodermical injection. At the end of the treatment, test the levels of precollagen Ⅲ （ pC Ⅲ ）, hyaluronic acid （HA） and laminin （LN） in the blood serum, and investigate the pathological chaneg of hepatic tissue. Results Panax Notoginsenosides can improve hepatic function and degrade the leels of pC Ⅲ, HA, LN on the rats models, and have the same delectable effect on the pathological change. While Panaxsaponin Rbl can not improve hepatic fibrosis, moreover it can damage the hepatic function. There are relationship between the degrees of pathological change and the levels of pC Ⅲ, HA. Conclusion： The levels of pC Ⅲ, HA in serum are reliable to evaluate hepatic fibrosis. Panaxsapoinin Rbl is not effective on hepatic fibrosis. Panaxsaponin Rbl is not one of the effective ingredients of Panax Notoginsenosides which can be used in hepatic fibrosis.